Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study

BACKGROUND: According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy. In that...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Se Jun, Kim, Hyunho, Shin, Kabsoo, Hong, Tae Ho, Suh, Ja Hee, Lee, Myung Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567553/
https://www.ncbi.nlm.nih.gov/pubmed/34732161
http://dx.doi.org/10.1186/s12885-021-08887-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567553/
https://www.ncbi.nlm.nih.gov/pubmed/34732161
http://dx.doi.org/10.1186/s12885-021-08887-1

Ejemplares similares